Dr Reddy's Laboratories Ltd banner

Dr Reddy's Laboratories Ltd
F:RDDA

Watchlist Manager
Dr Reddy's Laboratories Ltd Logo
Dr Reddy's Laboratories Ltd
F:RDDA
Watchlist
Price: 11.7 EUR -0.85% Market Closed
Market Cap: €1.9B

Gross Margin

65.8%
Current
Declining
by 3.1%
vs 3-y average of 68.9%

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
65.8%
=
Gross Profit
₹228.1B
/
Revenue
₹346.8B

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
65.8%
=
Gross Profit
€228.1B
/
Revenue
₹346.8B

Peer Comparison

Country Company Market Cap Gross
Margin
IN
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
1.1T INR
Loading...
ZA
Aspen Pharmacare Holdings Ltd
JSE:APN
48.4B ZAR
Loading...
US
Eli Lilly and Co
NYSE:LLY
960.1B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
579.4B USD
Loading...
CH
Roche Holding AG
SIX:ROG
281.2B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
228.3B GBP
Loading...
CH
Novartis AG
SIX:NOVN
235.6B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
295.4B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
Loading...
US
Pfizer Inc
NYSE:PFE
158B USD
Loading...

Market Distribution

Higher than 81% of companies in India
Percentile
81th
Based on 4 996 companies
81th percentile
65.8%
Low
-3 052.3% — 26.9%
Typical Range
26.9% — 53.3%
High
53.3% — 8 269.1%
Distribution Statistics
India
Min -3 052.3%
30th Percentile 26.9%
Median 39%
70th Percentile 53.3%
Max 8 269.1%

Dr Reddy's Laboratories Ltd
Glance View

In the bustling world of pharmaceuticals, Dr. Reddy's Laboratories Ltd. stands as a testament to innovation and resilience. Founded in 1984 by Dr. K. Anji Reddy, the company embarked on a journey to provide affordable and accessible medicine. Dr. Reddy's merged scientific rigor with a clear vision to eliminate health disparities worldwide. From creating complex generics and active pharmaceutical ingredients (APIs) to providing differentiated formulations, the company has built a strong foundation in both developed markets, like the United States and Europe, as well as in emerging markets such as India, Russia, and the CIS countries. This global footprint ensures that while many pharmaceutical companies are battling regulatory challenges and pricing pressures, Dr. Reddy's stays agile and competitive. The company's revenue streams primarily derive from its diverse portfolio of generic drugs, APIs, branded formulations, biologics, and proprietary products. Each sector is a strategic puzzle piece that enhances its market presence and ensures supply chain efficiency. Dr. Reddy's invests heavily in research and development to bolster its pipeline of future medications, aiming to address unmet medical needs and introduce value-added products. By leveraging strategic alliances and forging partnerships in development and distribution, the company adeptly navigates the complex landscape of the pharmaceutical industry, ensuring sustainable growth and reaffirming its commitment to affordable healthcare globally.

RDDA Intrinsic Value
HIDDEN
Show
What is Gross Margin?
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
How is Gross Margin calculated?

Gross Margin is calculated by dividing the Gross Profit by the Revenue.

Gross Margin
65.8%
=
Gross Profit
₹228.1B
/
Revenue
₹346.8B
What is Dr Reddy's Laboratories Ltd's current Gross Margin?

The current Gross Margin for Dr Reddy's Laboratories Ltd is 65.8%, which is below its 3-year median of 68.9%.

How has Gross Margin changed over time?

Over the last 3 years, Dr Reddy's Laboratories Ltd’s Gross Margin has decreased from 67.9% to 65.8%. During this period, it reached a low of 65.8% on Jan 1, 2026 and a high of 70.8% on Jun 30, 2024.

Back to Top